【摘要】 目的:探讨文拉法辛合并舒必利治疗精神分裂症的疗效和安全性。方法:将68例精神分裂症患者随机分为研究组与对照组,研究组给予文拉法辛合并舒必利治疗,对照组用利培酮治疗,疗程8周,用阳性与阴性症状量表(PANSS)、简明精神病评定量表(BPRS)以及治疗中出现的症状量表(TESS)评定疗效和安全性。结果:治疗8周研究组总有效率为88.24%,对照组为67.65%,两组比较差异有统计学意义(P<0.05)。治疗后两组PANSS及BPRS评分均有明显下降(P<0.05或P<0.01),研究组下降更显著(P<0.05)。结论:文拉法辛合并舒必利治疗精神分裂症阴性与阳性症状疗效可靠,不良反应小。更多还原

【Abstract】 Objective:To explore the efficacy and safety of venlafaxine combined with sulpiride in treatment of schizophrenia.Method:68 schizophrenia patients were divided into two groups randomly,34 were treated with venlafaxine combining sulpiride,34 with risperidone.The period of observation is 8 weeks.positive and negative symptom scale(PANSS),brief psychiatric rating scale(BPRS)and treatment emergent symptom scale(TESS)were used to assess efficacy and safety of the two groups.Results:Effective rates of the two groups were 88.24% and 67.65% respectively(P<0.05).Total scores of PANSS and BPRS decreased significantly in both groups after the treatment(P<0.05 or P<0.01),and venlafaxine combining sulpiride group decreased more.Conclusion:Venlafaxine combining sulpiride is an effective choice in treating positive and negative symptoms of schizophrenia with mild side effects更多还原